Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Epidemiology and Genomics Features of Klebsiella spp especially ST11-K64 CR-hvKP Outbreaks

PROVIDER: PRJNA638288 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR20999547_1.fastq.gz	Fastqsanger.gz
	SRR20999548.fastq.gz	Fastqsanger.gz
	SRR21808492_1.fastq.gz	Fastqsanger.gz
	SRR21808492_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 5

Similar Datasets

Project description:ST11-KL47 CR-hvKP

| PRJNA874350 | ENA

Project description:Clinical CR-hvKP ST11 strains collection

| PRJNA820335 | ENA

Project description:Clinical CR-hvKP ST11 strains collection

| PRJNA824258 | ENA

Project description:Non-mucoid CR-hvKp strain

| PRJNA819844 | ENA

Project description:Transcriptomic data of edited CR-hvKP

| PRJNA1047885 | ENA

Project description:draft genome sequence for the ST11 hvkp strains from China

| PRJNA391211 | ENA

Protective Effects of Recombinant Depolymerase Dep44 Against K64-CRKP-Induced Pulmonary Infection in a Murine Infection Model

Project description:Carbapenem-resistant Klebsiella pneumoniae (CRKP), particularly the K64 serotype, poses a severe clinical threat due to its high virulence and multidrug resistance. In this study, we investigated the gene expression profiles of host lung tissues to understand the pathogenesis of K64-CRKP infection and the therapeutic mechanism of Dep44, a capsule-degrading depolymerase. An acute pneumonia mouse model was established via intranasal infection with K64-CRKP. We performed high-throughput RNA sequencing (RNA-seq) on lung tissues from four experimental groups: the negative control group (healthy mice), the positive control group (K64-CRKP infected model), the treatment group (infected mice treated with Dep44), and the drug control group (healthy mice treated with Dep44). The analysis aims to elucidate the host immune response to K64-CRKP infection and evaluate how Dep44 treatment modulates these transcriptomic changes to exert its therapeutic effect.

2025-12-02 | GSE311904 | GEO

Project description:Response of the gut microbiota to CR-Hvkp infection

| PRJNA974556 | ENA

Integrated analysis of therapeutic efficacy and resistance mechanisms of lytic phages targeting ST218 K57 CR-hvKp

Project description:Clinical infection caused by carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) is gradually increasing and spreading across the world, and phage therapy is a viable application as an alternative to antibiotics. However, additional clinical application is still restricted by the phage resistance. In order to further explore the mechanism of phage resistance, particularly the difference between in vivo and in vitro. Here, we used a mouse intra-abdominal infection (IAI) model to evaluate the antibacterial properties of two lytic phages and further isolated and characterized phage-resistant mutants. Finally, we determined through genomic and transcriptomic analysis that most of the mutation sites in the resistant mutants were located in the capsular polysaccharides gene cluster. However, RM01 and RM12 developed phage resistance by downregulating capsular polysaccharide (CPS) and its transcriptional regulators without any mutations in the CPS gene. In summary, these findings provided further evidence in phage therapy, particularly in addressing the issue of CR-hvKP infections.

2025-09-18 | MTBLS12480 | MetaboLights

Two carbapenem-resistant Enterobacteriacea outbreaks: plasmids epidemiology

Project description:Two carbapenem-resistant Enterobacteriacea outbreaks: plasmids epidemiology

| PRJEB77420 | ENA